GlassScriptPhysician profile
Michelle F Edwards
NPI 1194039164
$3,683.42
in general payments reported to CMS, 2019-2025
19 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 89% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $824 · 2023: $460 · 2024: $1,146 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,734.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $652.60 | 2024-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $575.85 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $492.27 | 2024-2025 | Xifaxan, Trulance |
| Abbvie INC. | $419.35 | 2023-2025 | |
| Amgen INC. | $398.76 | 2022-2025 | Repatha, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $397.41 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2024 | Nuedexta |
| Paratek Pharmaceuticals, INC. | $125.00 | 2021 | |
| Corcept Therapeutics | $109.24 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.58 | 2023 | Jardiance |
| Vanda Pharmaceuticals INC. | $100.00 | 2025 | Fanapt |
| Viiv Healthcare Company | $32.07 | 2025 | Apretude |
| Abbott Laboratories | $28.52 | 2025 | Eterna |
| Actelion Pharmaceuticals US, INC. | $26.98 | 2024 | Uptravi, Opsumit |
| Xeris Pharmaceuticals, INC. | $22.89 | 2024 | Gvoke Hypopen |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $21.21 | 2024 | Shingrix |
| Dynavax Technologies Corporation | $19.46 | 2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $15.48 | 2025 | |
| Lilly USA, LLC | $13.75 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.